CASTLE ROCK, Colo., Oct. 14, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, ...
In 2010, after tests of AppyScore yielded poor results, the company's stock tanked and new executives were hired. Later, the company revamped the device, calling it Appy1, and changed the company name to Venaxis Inc. (Nasdaq: APPY).
Venaxis Inc. (NASDAQ: APPY) traded at $1.5 up 11.1 percent during After Hours sessions on 5000 total share volume. APPY traded -15.05 percent below its fifty-day moving average and -36.19 percent below its 200-day moving average.
This report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the structure and function of proteins.